Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers-Reference-Cited by-同舟云学术

Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers

Published:2021-05-25 Issue:6 Volume:4 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Bhalla Sheena¹,Zhu Huili²,Lin Jung‐Yi³,Özbek Umut³,Wilck Eric J.⁴,Chang Sanders⁴,Chen Xiuxu⁵,Ward Stephen⁶,Harpaz Noam⁶,Polydorides Alexandros D.⁶,Miller William⁶,Fiel Maria Isabel⁶,Modica Ippolito⁶,Fan Wen⁶,Zeizafoun Nebras⁶,Ang Celina¹

Affiliation:

1. Division of Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai New York USA

2. Department of Internal Medicine Icahn School of Medicine at Mount Sinai New York USA

3. Department of Population Health Science and Policy Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York USA

4. Department of Radiology Icahn School of Medicine at Mount Sinai New York USA

5. Department of Pathology Loyola University Medical Center Maywood Illinois USA

6. Department of Pathology Icahn School of Medicine at Mount Sinai New York USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1412

Reference31 articles.

1. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2. Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis

3. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer

4. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

5. FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of long non-coding RNAs HOTAIR, LINC00951, POLR2E and HULC polymorphisms with the risk of esophageal and esophagogastric junction cancer in a western population: a case-control study;Molecular Biology Reports;2024-02-01

2. Genetic Impact of HOTAIR, LINC00951, POLR2E and HULC Polymorphisms in Histopathological and Laboratory Prognostic Factors in Esophageal Cancer in the West: A Case-Control Study;Cancers;2024-01-26

3. Choosing Wisely Philippines: ten low-value or harmful practices that should be avoided in cancer care;ecancermedicalscience;2022-07-07